Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Addex Therapeutics Ltd ADR (ADXN)

Addex Therapeutics Ltd ADR (ADXN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Addex Completes $4.2 Million Equity Financing Globe Newswire - Tue Jul 26, 2022

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 26, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...

ADXN : 7.53 (-7.15%)
Addex Shareholders Approve All Resolutions at Annual General Meeting Globe Newswire - Tue May 10, 2022

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 10, 2022 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company...

ADXN : 7.53 (-7.15%)
Addex Reports Q1 2022 Financial Results Globe Newswire - Thu May 5, 2022

CHF14.9M ($16.1M) of cash and cash equivalents at March 31, 2022Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2 2022Phase...

ADXN : 7.53 (-7.15%)
Addex Convenes Annual General Meeting 2022 Globe Newswire - Thu Mar 31, 2022

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, March 31, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...

ADXN : 7.53 (-7.15%)
Addex to Present at the Bio-Europe Spring 2022 and Maxim Group – 2022 Virtual Growth Conferences Globe Newswire - Thu Mar 24, 2022

Geneva, Switzerland, March 24, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...

ADXN : 7.53 (-7.15%)
Addex Reports Full Year 2021 Financial Results and Provides Corporate Update Globe Newswire - Thu Mar 10, 2022

CHF20.5M ($22.5M) of cash and cash equivalents at December 31, 2021Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2...

ADXN : 7.53 (-7.15%)
Addex to Present at the Virtual Sachs Associates 3rd Annual European HealthTech and 15th Annual European Life Sciences CEO Forums Globe Newswire - Thu Feb 24, 2022

Geneva, Switzerland, February 24, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...

ADXN : 7.53 (-7.15%)
Addex to Present at the Swiss Equities Baader Virtual Conference Globe Newswire - Tue Jan 11, 2022

Geneva, Switzerland, January 11, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...

ADXN : 7.53 (-7.15%)
Addex to Present at the H.C. Wainwright BIOCONNECT Virtual Conference Globe Newswire - Thu Jan 6, 2022

Geneva, Switzerland, January 6 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...

ADXN : 7.53 (-7.15%)
Addex Raises $10.0 Million in Equity Financing Globe Newswire - Fri Dec 17, 2021

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...

ADXN : 7.53 (-7.15%)

Barchart Exclusives

NVDA Stock Looks Cheap to Value Buyers Based on its Huge FCF Margins Barchart - 5 minutes ago
Nvidia reported strong Q3 free cash flow margins and analysts have raised their revenue forecasts. This means NVDA stock could be undervalued by 26% with a price target of $179 per share. Shorting OTM puts is attracting interest. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot